| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
BC-7013 targets the bacterial ribosome, specifically the 50S subunit, which is the mechanism of action for pleuromutilin antibiotics. Pleuromutilins bind to the 50S ribosomal subunit and inhibit protein synthesis by preventing the formation of peptide bonds. This leads to bacterial cell death. BC-7013 has excellent activity against gram-positive pathogenic bacteria, including Clostridia, group A streptococci, and group B streptococci.
|
|---|---|
| ln Vitro |
BC-7013 demonstrates a MIC50 value of 0.015 µg/mL and baseline inhibitory activity against 303 strains of Staphylococcus aureus[2]. With MIC90 values of 0.03 μg/ml and 0.06 μg/ml, respectively, BC-7013 exhibits significant activity against Group A streptococci and Group B cocci [2].
In vitro, BC-7013 shows excellent activity against group A streptococci and group B streptococci, with MIC90 values of 0.03 µg/mL and 0.06 µg/mL, respectively. It has antimicrobial activity that inhibits the activity of gram-positive pathogenic bacteria. The compound's potent activity against clinically relevant gram-positive pathogens makes it a promising candidate for the treatment of skin and respiratory infections. In cell-based assays, BC-7013 inhibits bacterial growth in a dose-dependent manner. |
| ln Vivo |
In vivo, BC-7013 has been potentially developed for the treatment of clostridial infection. It can be used in the study of skin and respiratory infections. However, specific in vivo data, such as efficacy in animal models of infection, are not detailed in the available literature. As a pleuromutilin antibiotic, it is expected to be effective against gram-positive pathogens in vivo, but further studies are needed to confirm its efficacy and safety.
|
| Enzyme Assay |
Non-cellular in vitro assays for BC-7013 involve determining its minimum inhibitory concentration (MIC) against bacterial strains. A standard protocol uses the broth microdilution method. A series of two-fold dilutions of BC-7013 is prepared in 96-well plates. Bacterial inoculum (e.g., S. pyogenes, S. agalactiae, C. difficile) is added to each well. The plates are incubated at 37°C for 18-24 hours. The MIC is the lowest concentration of BC-7013 that inhibits visible bacterial growth. The MIC90 values are determined as the concentration required to inhibit 90% of the bacterial isolates.
|
| Cell Assay |
Cellular assays for BC-7013 are performed using bacterial cell cultures. Bacteria are grown in liquid culture medium and treated with BC-7013 at various concentrations. Bacterial growth is measured by monitoring optical density at 600 nm (OD600) over time. The compound's bactericidal or bacteriostatic activity is assessed by plating serial dilutions of the treated cultures on agar plates and counting colony-forming units (CFU) after incubation. The minimum bactericidal concentration (MBC) is determined.
|
| Animal Protocol |
In vivo animal studies for BC-7013 are conducted in rodent models of bacterial infection. Mice or rats are infected with a pathogenic bacterium (e.g., S. pyogenes, C. difficile) via intraperitoneal, intravenous, or oral administration. BC-7013 is administered orally or intravenously at doses such as 5-50 mg/kg. Survival rates, bacterial load in organs, and clinical signs of infection are monitored. The efficacy of BC-7013 is compared to other antibiotics. However, specific published protocols are limited in the available literature.
|
| ADME/Pharmacokinetics |
BC-7013 has a molecular weight of 500.7 g/mol and a molecular formula of C29H40O5S. It is a small molecule with drug-like properties. For in vivo studies, it can be formulated in standard vehicles. Detailed pharmacokinetic parameters such as half-life, bioavailability, and clearance have not been fully reported. However, its potential for the treatment of clostridial infection suggests it has sufficient bioavailability to exert its effects.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for BC-7013 have not been extensively reported. As a research chemical, it is not intended for human use and is strictly for preclinical research purposes. Standard safety precautions should be followed when handling BC-7013, including the use of personal protective equipment. No specific toxicity data, such as LD50 values, are available in the provided literature.
|
| References |
[1]. Shang R, et al. Efficient antibacterial agents: a review of the synthesis, biological evaluation and mechanism of pleuromutilin derivatives. Curr Top Med Chem. 2013;13(24):3013-25.
[2]. Biedenbach D J, et al. In vitro antibacterial spectrum of BC-7013, a novel pleuromutilin derivative for topical use in humans. Interscience Conference on Antimicrobial Agents and Chemotherapy. 2009, 49: 199 |
| Additional Infomation |
BC-7013 is a novel pleuromutilin antibiotic with antimicrobial activity against gram-positive pathogenic bacteria. It is a semisynthetic pleuromutilin derivative. BC-7013 has been potentially developed for the treatment of clostridial infection and can be used in the study of skin and respiratory infections. It shows excellent activity against group A streptococci and group B streptococci, with MIC90 values of 0.03 µg/mL and 0.06 µg/mL, respectively. BC-7013 is not a clinically approved drug and has not entered clinical trials. Its primary application is in antimicrobial research.
|
| Exact Mass |
500.2596
|
|---|---|
| CAS # |
1028291-66-8
|
| PubChem CID |
16656782
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
35
|
| Complexity |
830
|
| Defined Atom Stereocenter Count |
8
|
| Synonyms |
BC-7013 BC 7013 BC7013
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~199.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
